Gateway Chemical Technology revamped after acquisition

By Kirsty Barnes

- Last updated on GMT

Related tags: Chemistry

Chemir Analytical Services, the new owner of Gateway Chemical
Technology, has renamed the custom chemical analysis business
IQsynthesis in a revamp effort.

Gateway, which assists pharma firms in the early phase production of molecules for research and development, was bought by Chemir in May, as it sought to expand its range of pharmaceutical contract manufacturing services.

US-based Chemir Group already had a number of contract businesses under its umbrella - Chemir Analytical Services, Azopharma, a pharmaceutical contract service provider located in Florida, and CAS-MI, a laboratory serving the paints, coatings, and polymer industries - however, Gateway offered the firm the chance to branch out into a new specialty.

"As our Chemir group of companies serves more and more pharmaceutical clients, we recognise the need for a broad and diverse offering of contract service providers,"​ said Shri Thanedar, CEO of Chemir Analytical Services.

"Clients had been requesting synthetic chemistry services, and we sought an acquisition to best fill this need,"​ said Thanedar.

Specific synthesis services brought by newly-named IQsynthesis include molecules of pharmaceutical intermediates, bioorganic compounds, as well as specialty, fine and agrochemicals, from milligram to multi-kilogram scales.

"These molecules are the first steps in the development of new medications and therapies," said Robert Kaufman, president of IQsynthesis.

"We help large and small companies save time, stay on schedule, and attain their goal of creating molecules."

Other services include synthesis of analytical standards, metabolites, toxicology lot batches, stable isotope labelled compounds, key intermediates, custom surfactants, combinational platforms, extraction/purification of natural products and process development.

Chemir said it now plans to expand the laboratory space and number of staff at IQsynthesis, as well as develop new infrastructure and systems for cGMP-regulated synthesis.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars